Elutia Inc. Reports $7.6 Million Net Loss in Q2 2026, Revenue Declines 11.6%

Elutia Inc. reported a net loss of $7.6 million for the second quarter of 2026, a slight improvement from a net loss of $9.6 million in the same period last year. The company's revenue for the quarter was $2.4 million, down 11.6% from $2.7 million in the prior year, primarily due to a decline in sales from its Women’s Health segment. The Cardiovascular segment, however, saw a 55.4% increase in sales, contributing $1.1 million, as the company resumed direct sales following the termination of its distribution agreement with LeMaitre Vascular in April 2025.

For the first half of 2026, Elutia's total revenue was $5.5 million, a decrease of 2.8% compared to $5.7 million in the same period of 2025. The cost of goods sold also decreased significantly, from $2.9 million to $2.3 million, leading to an increase in gross profit margin from 49.8% to 58.6%. The company attributed this improvement to higher margins from direct sales to healthcare facilities, which replaced lower-margin distributor sales.

Elutia has undergone significant strategic changes, including the divestiture of its CIED Business in October 2025 for up to $88 million, which has allowed the company to focus on its drug-eluting biomatrix platform. The company also completed the sale of its Orthobiologics Business in November 2023, receiving approximately $14.6 million, with potential additional earn-out payments. Recently, Elutia entered into an Asset Purchase Agreement to divest its SimpliDerm Business, expecting to receive up to $11 million, which will further streamline its operations.

Operationally, Elutia's employee headcount has increased, reflecting its focus on research and development, particularly for its next-generation products, NXT-41 and NXT-41x. R&D expenses surged to $2.5 million in the second quarter, a 155.5% increase year-over-year, as the company intensifies its development efforts. The company also reported a decrease in litigation costs, which fell to $2.1 million from $4.0 million, indicating a resolution of several ongoing legal matters.

Looking ahead, Elutia anticipates continued operating losses and negative cash flows as it invests in product development and commercialization efforts. The company has approximately $19.9 million in cash and cash equivalents as of June 30, 2026, and plans to raise additional capital through equity offerings or debt financing to support its operations and growth initiatives. The future viability of Elutia will depend on its ability to generate cash flows from product sales and secure funding to finance its ongoing projects.